171 related articles for article (PubMed ID: 14645137)
1. Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta.
Patacchini R; Santicioli P; Giuliani S; Grieco P; Novellino E; Rovero P; Maggi CA
Br J Pharmacol; 2003 Dec; 140(7):1155-8. PubMed ID: 14645137
[TBL] [Abstract][Full Text] [Related]
2. Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors.
Camarda V; Song W; Marzola E; Spagnol M; Guerrini R; Salvadori S; Regoli D; Thompson JP; Rowbotham DJ; Behm DJ; Douglas SA; Calo' G; Lambert DG
Eur J Pharmacol; 2004 Sep; 498(1-3):83-6. PubMed ID: 15363979
[TBL] [Abstract][Full Text] [Related]
3. The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.
Behm DJ; Stankus G; Doe CP; Willette RN; Sarau HM; Foley JJ; Schmidt DB; Nuthulaganti P; Fornwald JA; Ames RS; Lambert DG; Calo' G; Camarda V; Aiyar NV; Douglas SA
Br J Pharmacol; 2006 May; 148(2):173-90. PubMed ID: 16547525
[TBL] [Abstract][Full Text] [Related]
4. Urotensin-II receptor ligands. From agonist to antagonist activity.
Grieco P; Carotenuto A; Campiglia P; Marinelli L; Lama T; Patacchini R; Santicioli P; Maggi CA; Rovero P; Novellino E
J Med Chem; 2005 Nov; 48(23):7290-7. PubMed ID: 16279788
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist.
Behm DJ; Herold CL; Ohlstein EH; Knight SD; Dhanak D; Douglas SA
Br J Pharmacol; 2002 Oct; 137(4):449-58. PubMed ID: 12359626
[TBL] [Abstract][Full Text] [Related]
6. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.
Behm DJ; Harrison SM; Ao Z; Maniscalco K; Pickering SJ; Grau EV; Woods TN; Coatney RW; Doe CP; Willette RN; Johns DG; Douglas SA
Br J Pharmacol; 2003 May; 139(2):464-72. PubMed ID: 12770952
[TBL] [Abstract][Full Text] [Related]
7. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents.
Camarda V; Rizzi A; Calò G; Gendron G; Perron SI; Kostenis E; Zamboni P; Mascoli F; Regoli D
Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):141-9. PubMed ID: 11819032
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen5,DTrp7,Dab8]urotensin II(4-11) (UFP-803).
Camarda V; Spagnol M; Song W; Vergura R; Roth AL; Thompson JP; Rowbotham DJ; Guerrini R; Marzola E; Salvadori S; Cavanni P; Regoli D; Douglas SA; Lambert DG; Calò G
Br J Pharmacol; 2006 Jan; 147(1):92-100. PubMed ID: 16273120
[TBL] [Abstract][Full Text] [Related]
9. The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors.
Herold CL; Behm DJ; Buckley PT; Foley JJ; Wixted WE; Sarau HM; Douglas SA
Br J Pharmacol; 2003 May; 139(2):203-7. PubMed ID: 12770925
[TBL] [Abstract][Full Text] [Related]
10. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists.
Rossowski WJ; Cheng BL; Taylor JE; Datta R; Coy DH
Eur J Pharmacol; 2002 Mar; 438(3):159-70. PubMed ID: 11909607
[TBL] [Abstract][Full Text] [Related]
11. Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity.
Song W; McDonald J; Camarda V; Calo G; Guerrini R; Marzola E; Thompson JP; Rowbotham DJ; Lambert DG
Naunyn Schmiedebergs Arch Pharmacol; 2006 May; 373(2):148-57. PubMed ID: 16596397
[TBL] [Abstract][Full Text] [Related]
12. Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors.
Behm DJ; Herold CL; Camarda V; Aiyar NV; Douglas SA
Eur J Pharmacol; 2004 May; 492(2-3):113-6. PubMed ID: 15178353
[TBL] [Abstract][Full Text] [Related]
13. New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide.
Grieco P; Carotenuto A; Campiglia P; Gomez-Monterrey I; Auriemma L; Sala M; Marcozzi C; d'Emmanuele di Villa Bianca R; Brancaccio D; Rovero P; Santicioli P; Meini S; Maggi CA; Novellino E
J Med Chem; 2009 Jul; 52(13):3927-40. PubMed ID: 19432421
[TBL] [Abstract][Full Text] [Related]
14. A new ligand for the urotensin II receptor.
Camarda V; Guerrini R; Kostenis E; Rizzi A; Calò G; Hattenberger A; Zucchini M; Salvadori S; Regoli D
Br J Pharmacol; 2002 Oct; 137(3):311-4. PubMed ID: 12237249
[TBL] [Abstract][Full Text] [Related]
15. Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor.
Carotenuto A; Auriemma L; Merlino F; Yousif AM; Marasco D; Limatola A; Campiglia P; Gomez-Monterrey I; Santicioli P; Meini S; Maggi CA; Novellino E; Grieco P
J Med Chem; 2014 Jul; 57(14):5965-74. PubMed ID: 24992374
[TBL] [Abstract][Full Text] [Related]
16. Effects of urotensin II and its specific receptor antagonist urantide on rat vascular smooth muscle cells.
Zhao J; Zhang SF; Shi Y; Ren LQ
Bosn J Basic Med Sci; 2013 May; 13(2):78-83. PubMed ID: 23725502
[TBL] [Abstract][Full Text] [Related]
17. Urantide alleviates the symptoms of atherosclerotic rats in vivo and in vitro models through the JAK2/STAT3 signaling pathway.
Wang T; Xie L; Bi H; Li Y; Li Y; Zhao J
Eur J Pharmacol; 2021 Jul; 902():174037. PubMed ID: 33891969
[TBL] [Abstract][Full Text] [Related]
18. Urantide conformation and interaction with the urotensin-II receptor.
Brancaccio D; Limatola A; Campiglia P; Gomez-Monterrey I; Novellino E; Grieco P; Carotenuto A
Arch Pharm (Weinheim); 2014 Mar; 347(3):185-92. PubMed ID: 24357333
[TBL] [Abstract][Full Text] [Related]
19. Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.
Douglas SA; Behm DJ; Aiyar NV; Naselsky D; Disa J; Brooks DP; Ohlstein EH; Gleason JG; Sarau HM; Foley JJ; Buckley PT; Schmidt DB; Wixted WE; Widdowson K; Riley G; Jin J; Gallagher TF; Schmidt SJ; Ridgers L; Christmann LT; Keenan RM; Knight SD; Dhanak D
Br J Pharmacol; 2005 Jul; 145(5):620-35. PubMed ID: 15852036
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships of a novel series of urotensin II analogues: identification of a urotensin II antagonist.
Chatenet D; Dubessy C; Boularan C; Scalbert E; Pfeiffer B; Renard P; Lihrmann I; Pacaud P; Tonon MC; Vaudry H; Leprince J
J Med Chem; 2006 Nov; 49(24):7234-8. PubMed ID: 17125276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
